USAID Funding Cuts Threaten Global Access to New HIV Prevention Drug
At the Aids 2026 Conference in Rio de Janeiro, experts highlighted the potential of lenacapavir, an injectable HIV prevention drug, to significantly reduce new HIV cases globally. The World Health Organization (WHO) has recommended prioritizing the expansion of lenacapavir access due to its effectiveness and the convenience of requiring only two injections annually. However, the dissolution of USAID, which previously provided a substantial portion of global HIV prevention funding, has led to a dramatic decline in investment. This reduction in funding is impacting the availability of the drug and the ability of organizations to reach those in need, particularly in regions facing poverty, stigma, or geographical barriers.